Analysis Headlines

Analysis: Sales of first big COVID-19 drug, remdesivir, may disappoint

Investors betting on big profits from COVID-19 treatments may get an unwelcome surprise when Gilead Sciences Inc reports quarterly results this month. Its remdesivir, the first important coronavirus treatment, has not been used as much as first expected and faces complex insurance reimbursement issues.

Top News Video

Top News